Search Results - "Monteiro FSM"

Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?

Authors: Cerbone L Roviello G Calabrò F et al.

Source: Frontiers in immunology [Front Immunol] 2026 Feb 24; Vol. 17, pp. 1667155. Date of Electronic Publication: 2026 Feb 24 (Print Publication: 2026).

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

An agent-based learning model integrating sex differences in renal cell carcinoma.

Authors: Merelli E Taha T Caputo M et al.

Source: Frontiers in immunology [Front Immunol] 2026 Apr 01; Vol. 17, pp. 1779638. Date of Electronic Publication: 2026 Apr 01 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Authors: Mollica V Massari F Fujita K et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2026 Mar 24; Vol. 75 (4). Date of Electronic Publication: 2026 Mar 24.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Infusion-Related Reactions Among Cancer Patients Receiving Immune Checkpoint Inhibitors: The ARON-MOUSEION-013 Systematic Review and Meta-Analysis.

Authors: Vitale E Rizzo A Maistrello L et al.

Source: Drug design, development and therapy [Drug Des Devel Ther] 2025 Dec 13; Vol. 19, pp. 11107-11118. Date of Electronic Publication: 2025 Dec 13 (Print Publication: 2025).

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study.

Authors: Kopp RM Massari F Grande E et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Nov 14; Vol. 74 (12), pp. 374. Date of Electronic Publication: 2025 Nov 14.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1).

Authors: Santini D Li H Roviello G et al.

Source: Targeted oncology [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 893-903. Date of Electronic Publication: 2024 Sep 17.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2^EV study.

Authors: Fiala O Buti S Fujita K et al.

Source: Clinical & experimental metastasis [Clin Exp Metastasis] 2025 Feb 20; Vol. 42 (2), pp. 18. Date of Electronic Publication: 2025 Feb 20.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8409970 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7276 (Electronic) Linking ISSN: 02620898 NLM ISO Abbreviation: Clin Exp Metastasis Subsets: MEDLINE

Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.

Authors: Rizzo A Monteiro FSM Mollica V et al.

Source: Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Dec 16; Vol. 42 (1), pp. 3. Date of Electronic Publication: 2024 Dec 16.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8409970 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7276 (Electronic) Linking ISSN: 02620898 NLM ISO Abbreviation: Clin Exp Metastasis Subsets: MEDLINE

Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2^EV Study.

Authors: Fiala O Massari F Basso U et al.

Source: Targeted oncology [Target Oncol] 2024 Nov; Vol. 19 (6), pp. 905-915. Date of Electronic Publication: 2024 Oct 01.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study.

Authors: Pichler R Klinglmair G Binz K et al.

Source: Clinical & experimental metastasis [Clin Exp Metastasis] 2025 Nov 21; Vol. 43 (1), pp. 1. Date of Electronic Publication: 2025 Nov 21.

Publication Type: Journal Article

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8409970 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7276 (Electronic) Linking ISSN: 02620898 NLM ISO Abbreviation: Clin Exp Metastasis Subsets: MEDLINE

¹⁷⁷Lu-PSMA vs. cabazitaxel in patients with castration-resistant prostate cancer: Real-world efficacy and safety data from the ARON-3 study.

Authors: Mandel P Groener D Follacchio G et al.

Source: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 Oct 16; Vol. 229, pp. 115789. Date of Electronic Publication: 2025 Sep 12.

Publication Type: Journal Article; Multicenter Study; Comparative Study

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

Bioinformatics and clinical analysis reveal the potential diagnostic and prognostic role of DLD for pan cancer and renal carcinoma.

Authors: Sun F Zhang D Ma X et al.

Source: Discover oncology [Discov Oncol] 2026 Feb 17; Vol. 17 (1), pp. 328. Date of Electronic Publication: 2026 Feb 17.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101775142 Publication Model: Electronic Cited Medium: Internet ISSN: 2730-6011 (Electronic) Linking ISSN: 27306011 NLM ISO Abbreviation: Discov Oncol Subsets: PubMed not MEDLINE

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study.

Authors: Porta C Massari F Taha T et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 09; Vol. 74 (7), pp. 196. Date of Electronic Publication: 2025 May 09.

Publication Type: Journal Article

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.

Authors: Monteiro FSM Fiala O Massari F et al.

Source: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Apr; Vol. 22 (2), pp. 305-314.e3. Date of Electronic Publication: 2023 Nov 24.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE

Efficacy and safety of immune-based combinations in metastatic hepatocellular carcinoma: a systematic review and network meta-analysis.

Authors: de Moura ACC Rizzo A Santos TAB et al.

Source: BMC cancer [BMC Cancer] 2026 Mar 25; Vol. 26 (1). Date of Electronic Publication: 2026 Mar 25.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE; In Process

Hyponatremia in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-014 meta-analysis.

Authors: Vitale E Maistrello L Ciccimarra F et al.

Source: Cancer metastasis reviews [Cancer Metastasis Rev] 2026 Mar 17; Vol. 45 (2). Date of Electronic Publication: 2026 Mar 17.

Publication Type: Journal Article; Meta-Analysis; Systematic Review; Review

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8605731 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7233 (Electronic) Linking ISSN: 01677659 NLM ISO Abbreviation: Cancer Metastasis Rev Subsets: MEDLINE

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.

Authors: Roviello G Molina-Cerrillo J Massari F et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 Jan 03; Vol. 74 (2), pp. 65. Date of Electronic Publication: 2025 Jan 03.

Publication Type: Journal Article; Multicenter Study; Comparative Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.

Authors: Rizzo A Monteiro FSM Mollica V et al.

Source: Clinical & experimental metastasis [Clin Exp Metastasis] 2024 Dec 30; Vol. 42 (1), pp. 9. Date of Electronic Publication: 2024 Dec 30.

Publication Type: Journal Article; Meta-Analysis; Systematic Review

Journal Info: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 8409970 Publication Model: Electronic Cited Medium: Internet ISSN: 1573-7276 (Electronic) Linking ISSN: 02620898 NLM ISO Abbreviation: Clin Exp Metastasis Subsets: MEDLINE

Bone metastases in advanced urothelial carcinoma patients receiving enfortumab vedotin: A Real-World study from the ARON-2^EV project.

Authors: Rizzo A Myint ZW Ciccimarra F et al.

Source: Clinical and experimental medicine [Clin Exp Med] 2025 Dec 29; Vol. 26 (1), pp. 75. Date of Electronic Publication: 2025 Dec 29.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Electronic Cited Medium: Internet ISSN: 1591-9528 (Electronic) Linking ISSN: 15918890 NLM ISO Abbreviation: Clin Exp Med Subsets: MEDLINE

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.

Authors: Rizzo, Mimma Soares, Andrey Grande, Enrique et al.

Source: Scientific Reports. 8/27/2024, Vol. 14 Issue 1, p1-11. 11p.